[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CN101370524A - 脂肽组合物 - Google Patents

脂肽组合物 Download PDF

Info

Publication number
CN101370524A
CN101370524A CNA2006800511655A CN200680051165A CN101370524A CN 101370524 A CN101370524 A CN 101370524A CN A2006800511655 A CNA2006800511655 A CN A2006800511655A CN 200680051165 A CN200680051165 A CN 200680051165A CN 101370524 A CN101370524 A CN 101370524A
Authority
CN
China
Prior art keywords
cyclodextrin
lipopeptid
derivant
weight
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2006800511655A
Other languages
English (en)
Chinese (zh)
Inventor
哈拉尔德·拉比斯钦斯基
斯特凡·佩尔泽
霍斯特·普列费特
安德列亚斯·旺特
斯文-埃里克·沃勒特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merlion Pharmaceuticals GmbH
Original Assignee
Merlion Pharmaceuticals GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merlion Pharmaceuticals GmbH filed Critical Merlion Pharmaceuticals GmbH
Publication of CN101370524A publication Critical patent/CN101370524A/zh
Pending legal-status Critical Current

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nanotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CNA2006800511655A 2005-11-21 2006-11-20 脂肽组合物 Pending CN101370524A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102005056194A DE102005056194A1 (de) 2005-11-21 2005-11-21 Neue Lipopeptid Zusammensetzungen
DE102005056194.2 2005-11-21

Publications (1)

Publication Number Publication Date
CN101370524A true CN101370524A (zh) 2009-02-18

Family

ID=37763891

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2006800511655A Pending CN101370524A (zh) 2005-11-21 2006-11-20 脂肽组合物

Country Status (7)

Country Link
EP (1) EP1951311A1 (de)
CN (1) CN101370524A (de)
AU (1) AU2006314942A1 (de)
CA (1) CA2630497A1 (de)
DE (1) DE102005056194A1 (de)
MX (1) MX2008006476A (de)
WO (1) WO2007057005A1 (de)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104768966A (zh) * 2012-09-24 2015-07-08 中化帝斯曼制药有限公司荷兰公司 生产环肽的方法
CN113811290A (zh) * 2019-05-10 2021-12-17 埃克斯利亚制药有限公司 达托霉素水性制剂

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4411025A1 (de) * 1994-03-30 1995-10-05 Hoechst Ag Lipopeptid-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung
DE19807972A1 (de) * 1998-02-25 1999-08-26 Hoechst Marion Roussel De Gmbh Lipopeptidantibiotika-Calciumsalze, Verfahren zu ihrer Herstellung und Verwendung
JP4870314B2 (ja) * 2000-05-02 2012-02-08 セラヴァンス, インコーポレーテッド シクロデキストリンを含むグリコペプチド抗生物質組成物
US7527807B2 (en) * 2000-06-21 2009-05-05 Cubist Pharmaceuticals, Inc. Compositions and methods for increasing the oral absorption of antimicrobials
UA82824C2 (uk) * 2000-06-21 2008-05-26 К'Юбіст Фармасьютікалз, Інк. Композиція і спосіб поліпшення перорального всмоктування протимікробних засобів
WO2002032459A2 (en) * 2000-10-17 2002-04-25 Massachusetts Institute Of Technology Method of increasing the efficacy of antibiotics by complexing with cyclodextrins

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104768966A (zh) * 2012-09-24 2015-07-08 中化帝斯曼制药有限公司荷兰公司 生产环肽的方法
CN104768966B (zh) * 2012-09-24 2018-11-02 中化帝斯曼制药有限公司荷兰公司 生产环肽的方法
CN113811290A (zh) * 2019-05-10 2021-12-17 埃克斯利亚制药有限公司 达托霉素水性制剂

Also Published As

Publication number Publication date
WO2007057005A1 (de) 2007-05-24
CA2630497A1 (en) 2007-05-24
AU2006314942A1 (en) 2007-05-24
EP1951311A1 (de) 2008-08-06
DE102005056194A1 (de) 2007-07-12
MX2008006476A (es) 2008-09-26

Similar Documents

Publication Publication Date Title
EP2062582B1 (de) Antibiotische zusammensetzung mit beta-lactam-antibiotika, aminoglykosiden und puffern
US4767874A (en) Stable freeze-dried preparations of an anticancer platinum complex
RU2734236C2 (ru) Композиции бендамустина и циклополисахарида
CA2668733C (en) Liquid preparation comprising a complex of pimobendan and cyclodextrin
AU742036B2 (en) Pharmaceutical compositions containing cyclodextrins and taxoids
EP0091782B1 (de) Einschlussverbindung von Antibiotika der Lankacidingruppe sowie deren Verwendung
KR19990064137A (ko) 경구투여용 항균성 조성물
KR20010034240A (ko) 약학 조성물
FR2596651A1 (fr) Nouveaux liposomes a base de phosphatidylinositolmannosides, et compositions pharmaceutiques les contenant
TWI246926B (en) Pharmaceutical dronedarone composition for parenteral administration
KR100700963B1 (ko) 켐토테신의 다당체 유도체를 함유하는 동결건조된 액상제제
PT2047857E (pt) Agente para fins de injecção compreendendo um antibióitco, e solução para injecção compreendendo o agente
US7795207B2 (en) Lipopeptide compositions
CA2389304A1 (en) Compositions and methods for controlled-release delivery and increased potency of pharmaceuticals via hydrophobic ion-pairing
FR2499854A1 (fr) Medicament contenant de la cyclodextrine utile notamment pour provoquer la proliferation des bifidobacteries intestinales
CN101370524A (zh) 脂肽组合物
JPH0764884B2 (ja) シクロデキストリン組成物
JP3597239B2 (ja) 安定な点眼剤
US20040157797A1 (en) Drug formulation and delivery using crystalline methylated cyclodextrins
JP2000509013A (ja) ウルソデオキシコール酸またはタウロウルソデオキシコール酸、強塩基、およびトロメタモールを含む注射可能な薬学的組成物
CA2486571C (en) Pharmaceutical composition
EP1994938A1 (de) Neue Lipoglycodepsipeptid-Zusammensetzungen
KR20090069264A (ko) 주사 투여용 약제학적 조성물
JP2002542201A (ja) シュードマイシン抗真菌組成物およびその使用方法
RU2800287C1 (ru) Антибактериальная композиция грамицидина с, способ ее получения и применения

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20090218